CompanyAMLXNasdaqCambridge, MA

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals develops investigational therapies for endocrine conditions and neurodegenerative diseases.

SEC EDGAR ClinicalTrials.gov amylyx.com

10-KSep 24Latest SEC filing, period to Jun 30

Sep 8Latest story

September 2026

Amylyx signs two manufacturing deals to secure avexitide drug substance supply

Sep 8PartnershipAmylyx Pharmaceuticals, Inc.avexitide

August 2026

Amylyx prices 14.09 million-share offering at $35.50 after LUCIDITY topline win

Aug 20FinancingAmylyx Pharmaceuticals, Inc.avexitide

Amylyx prices public offering of 14.09 million shares at $35.50

Aug 20PartnershipAmylyx Pharmaceuticals, Inc.avexitide

Amylyx reports positive Phase 3 results for avexitide in post-bariatric hypoglycemia

Aug 18Clinical readoutAmylyx Pharmaceuticals, Inc.avexitide

Amylyx completes LUCIDITY dosing period, sets late-August/early-September readout

Aug 6Quarterly updateAmylyx Pharmaceuticals, Inc.avexitide